2022 Scientific Sessions of the National Lipid Association (NLA)

by EpicentRx | Jun 1, 2022 | Conferences

June 2022, San Francisco, California Poster: The NLRP3 inhibitor and Nrf2 agonist, RRx-001, ameliorates non-alcoholic fatty liver disease (NAFLD/NASH) in rats

American Society of Clinical Oncology (ASCO) Annual Meeting

by EpicentRx | May 27, 2022 | Conferences

June 2022, Chicago, Illinois Poster: Phase 2 pilot trial of RRx-001 as an anti-mucositis agent in head and neck cancer patients treated with chemoradiation (PREVLAR)

American Thoracic Society (ATS) Respiratory Innovation Summit

by EpicentRx | May 27, 2022 | Conferences

May 2022, San Francisco, California Oral Presentation: Inflammation and Immunology: Feature Company Showcase Poster: The ABCs of COVID-19 Related ARDS Treatment Poster: N-VAX, a universal coronavirus vaccine Poster: RRx-001, an NLRP3 inflammasome inhibitor,...

EpicentRx Announces Poster Presentation for Phase 2 Randomized Clinical Trial with RRx-001 as an Anti-Mucositis Agent in Locally Advanced Head and Neck Cancer at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

by EpicentRx | May 27, 2022 | 2022, Press Releases

TORREY PINES, Calif., June 1, 2022 — EpicentRx, Inc, a privately-held clinical-stage biotechnology company at the forefront of developing oncolytic viruses and small molecules for the treatment of cancer and other inflammatory-driven diseases, today announced...

Deliberate Serendipity: Dr. Tony Reid, CEO of EpicentRx, Presents on AdAPT-001 at the International American Thoracic Society (ATS) Conference in Fibrosis

by EpicentRx | May 26, 2022 | Blog

“You gotta be moving to trip over something.” To rapt attention in a filled-to-capacity conference hall of the San Francisco Marriott hotel, Dr. Tony R. Reid, an invited speaker of a selected abstract at the International American Thoracic Society (ATS)...